Ophthalmologists and Retinal Specialists
Turn on The Power of Compounding. See the Wedgewood Pharmacy difference.
When your choice for treating wet age-related macular degeneration and other ophthalmic diseases is a custom-compounded medication, turn to Wedgewood Pharmacy. When your patients depend on compounds as part of their therapies, you can rely on us to provide more choices, consistency, quality, world-class customer care and convenience. We provide compounded medications for ophthalmic use in dosage forms that include drops and pre-filled syringes.
If you don't see the compounded preparation your patient needs below, use our powerful search engine above or call 877.357.6613 for a formulation consultation with one of our specialized pharmacists.
You can prescribe these compounded ophthalmic preparations from Wedgewood Pharmacy.
Featured Compounded Medication
Bevacizumab (Avastin®) 25mg/ml pre-filled syringes
We offer three dosage sizes of pre-filled, single-dose Bevacizumab (Avastin) syringes, prepared in a state-of-the-art aseptic environment:
- 0.05ml (insulin syringe 31g, 5/16th inch);
- 0.12ml; and
- 0.15ml.
How Wedgewood Pharmacy compounds Bevacizumab
The staff of pharmacists and technicians who compound Bevacizumab are devoted exclusively to compounding sterile compounds. Each person is rigorously trained in aseptic techniques and is re-certified twice each year. Bevacizumab is prepared, packaged and dispensed using a method adapted from a process developed at the Bascom Palmer Eye Institute Pharmacy. During the compounding process, the Avastin vial stopper remains securely in place, protecting the solution from inadvertent contamination during handling and filling in a laminar flow hood. Our process has been tested and verified by numerous pharmacists during a six-year period, during which Wedgewood Pharmacy has compounded more than a quarter million doses for more than 400 retinal specialists located in 39 states and Puerto Rico.
Our state-of-the-art compounding facility complies with the U.S. Pharmacopeia standard <797> and includes a suite of four ISO Class 6/Class 1000 clean rooms with ISO Class 5/Class 100 laminar airflow hoods. The rooms are HEPA-filtered, cleaned daily and tested internally each week. Twice per year, an independent environmental monitoring service verifies that our clean rooms meet ISO class standards.
Research in Our Learning Center
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration," New England Journal of Medicine, April 28, 2011
Bevacizumab In the News